HMAs and cytarabine can downregulate the expression of MCL1, and may exert a synergistic effect with venetoclax to interfere with the energy metabolism of AML stem cells and kill tumor cell [50, 53, 54]. The gene discussed is MCL1; the disease is neoplasm.